Praxis Precision Medicines (PRAX) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
9 Nov, 2026Ulixacaltamide review and launch
FDA late-cycle meeting completed; discussions focused largely on label wording, with management describing strong alignment and expecting approval by January, subject to FDA decisions.
Management expects a broad adult essential tremor label, with no efficacy differences identified across subgroups; alternative titration is likely to be included to help address discontinuations.
Launch preparations are underway; shipment can begin immediately after approval if no scheduling is required, while a scheduling process could delay shipment by a few months.
Management views no scheduling as preferable for supply-chain simplicity; if scheduled, a rating of four or five was described as the maximum possibility.
Potential post-approval studies remain under discussion; management suggested any requirements might involve preclinical work or special populations, with no expected major impact.
Relutrigine review
Late-cycle discussions involved information requests and questions requiring resolution; there were no pending information requests at the time of the conference.
Review was characterized as somewhat behind ulixacaltamide, with more meaningful open questions and less certainty; management said the interactions had not changed launch plans and continued to expect approval.
The PDUFA date was identified as December 27; management said the review questions were being addressed ahead of a decision.
EMERALD and pipeline updates
EMERALD reached last patient, last visit; data cleaning and quality checks are ongoing, and management plans to report results during the NDA review period after completing detailed data QC.
Enrollment pace was similar across the first and second halves, leaving a substantial open-label cohort with completed visits at readout; management expects this to add context for prescribers.
EMERALD is etiologically driven; SCN1A patients account for a low single-digit percentage of enrollment, which management said could not change the study outcome.
Management described a strong long-term disease and seizure-control signal and sees EMERALD as part of the planned evidence package for SCN2A and SCN8A, subject to FDA review comments.
EMBRAVE3 alone has a very high likelihood of serving as the elsunersen NDA study; an FDA Type B meeting was completed, with submission timing to be updated later that week.
POWER2 is underway; POWER3 is planned to start next year, following additional expert input on study design.
Latest events from Praxis Precision Medicines
- Ulixacaltamide nears its PDUFA as commercial readiness and pipeline catalysts advance.PRAX
UBS Global Biopharma Conference 2026 - Two near-term launches anchor a pipeline with >$20B in peak-sales guidance.PRAX
Investor Day 2026 - Two NDAs near FDA decisions as $1.3B in liquidity supports operations into 2028.PRAX
Q3 2026 - $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Four CNS therapies with blockbuster potential target >$20B peak sales by 2028.PRAX
Corporate presentation - Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAX
Jefferies Global Healthcare Conference 2025 - Accelerated clinical and regulatory strategies are driving earlier market entry for key therapies.PRAX
Fireside Chat - Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAX
Q4 2025 - Multiple late-stage clinical readouts and $433.8M cash support operations into 2027.PRAX
Q2 2024